# Jason Hier

Jason Hier helps life sciences organizations connect strategy to execution through collaborative, visual business roadmaps, using SharpCloud to align teams, prioritize work, and track risks and progress.

- Profile: https://b2binfluencer.marketing/creators/jason-hier/
- LinkedIn: https://www.linkedin.com/in/jasonhier
- LinkedIn followers: 4,859
- YouTube: https://www.youtube.com/channel/UCApxBiQYHm3Swhdq1aFuVXg
- Based on 10 dated posts, latest 2026-09-30

## Summary

Most useful for life sciences roadmapping content or workshops that connect strategy to execution across functions.

- Best for: A life sciences consulting firm selling roadmap or strategy-to-execution services to pharma leaders.
- Not for: A broad-reach paid sponsorship or campaign measured mainly on impressions or consumer-scale reach.
- Check first: Ask for recent post-level results and audience breakdown by job function, seniority, and company.

### Takeaways

- Strategy is not the hard part; connecting it across teams is.
- Prioritization has to be co-created in the open.
- Risk is a visibility problem, not a forecasting problem.

## Main ideas

- **Strategy isn’t the hard part; connecting it is**: Jason Hier argues that organizations rarely struggle to create strategy; they struggle to connect it. The disconnect shows up most clearly between corporate and site teams in both R&D and manufacturing. A roadmap translates high-level plans into workstreams with owners and timing, so teams can see what needs to happen and when.
- **Aim for “sufficiently aligned,” not perfectly aligned**: The recurring failure is that research, regulatory, product and commercial goals and milestones are not aligned, leading to delays, rework and missed opportunities. Jason Hier’s target is not total agreement but “sufficiently aligned”: teams can see and connect the alignment relationships between the moving parts.
- **Prioritization has to be co-created in the open**: Jason Hier argues that there is always more work than budgets or teams can support, and that siloed, inconsistent or absent prioritization spreads resources across underperforming efforts. The remedy is for key stakeholders to select the “must haves” together in a visual, interactive format, building buy-in rather than imposing a ranking from above.
- **Risk is a visibility problem, not a forecasting problem**: Rather than predict trouble, Jason Hier argues for making dependencies, gaps and bottlenecks visible before they cause costly delays. Spreadsheets and presentations are inadequate for tracking the move from discovery into development and from tech transfer into manufacturing; live visuals and current data let leaders steer proactively, reprioritize quickly and keep delivery tied to strategic goals.
- **One shared picture beats departmental silos**: The silo problem plays out function by function, with R&D, manufacturing, quality and commercial teams each working from their own view. A single source of truth offers a practical coordination fix rather than a culture program: when everyone sees the same picture, collaboration takes less effort.
- **Apply the same discipline to your own business**: In a year-end reflection, Jason Hier admits to helping clients find alignment while working in the business rather than on it—delivering projects instead of planning. Tolerated items that cause no immediate pain accumulate, the argument goes, and seeing them together reveals connections and a strongly positive cause and effect. The stated intention is to have a business roadmap in place for the coming year.

## Work to read

- [Why Every Life Sciences Leader Needs a Business Roadmap](https://www.linkedin.com/posts/jasonhier_lifesciences-businessroadmap-sharpcloud-activity-7351528666440290304-zKQR)
- [The Missing Link in Life Sciences Strategy? A Roadmap.](https://www.linkedin.com/posts/jasonhier_pharmastrategy-roadmap-lifesciences-activity-7399026266257084418-6YIH)
- [How well has 2025 gone for you?](https://www.linkedin.com/posts/jasonhier_roadmap-businessstrategy-strategicplanning-activity-7401553329216049152-Dw2N)

## Brand relationships

- **Roelto** (disclosed_partnership)
- **SharpCloud** (mention)

## Partnerships

Jason Hier promotes roadmap work through Roelto, which the posts describe as supporting life sciences organisations with collaborative, visual roadmaps powered by SharpCloud. Two posts end with an open “Let's talk” invitation. They present service marketing for roadmap consulting, not creator sponsorship inventory: one lists the problems a business roadmap addresses (cross-functional alignment across R&D, compliance, manufacturing and market access; proactive risk management of dependencies and bottlenecks; collaborative prioritisation such as a MoSCoW grid), while another frames a roadmap as the missing link connecting strategy to execution across R&D, Manufacturing, Quality and Commercial teams. The posts disclose no sponsorship packages, content-collaboration terms, rates, deliverables, audience specifications or sponsored-content format. A brand or agency should ask directly about partnership format, disclosure, deliverables, audience specifications, rates and who holds the commercial relationship.

## Alternatives

- Patrick Ansems: Choose Patrick Ansems over Jason Hier for the same strategy-to-execution workshop or content campaign when the consulting firm's credibility depends on digital transformation, industrial AI, digital twins, and scaling therapies from molecule to market. Ansems's posts give a named framework (the Digital Organism: Mind, Heart, Body, Soul) and specific arguments about AI as a context problem, trapped manufacturing capacity, Eroom's Law, and connecting scientific intent to equipment reality. This is a stronger match if the buyer is a manufacturing, digital, or R&D technology leader who wants a conceptual architecture and event-backed point of view rather than a collaborative prioritisation exercise.
- Dan Lewis: Choose Dan Lewis over Jason Hier when the need is current pharma industry news, deal and restructuring context, and manufacturing-operations detail rather than a roadmap method. Lewis's posts show a regular industry-roundup format covering licensing, FDA leadership changes, layoffs, top-selling drugs, supply-security policy, and AI drug-design funding, plus a first-person account of the SimoTech acquisition aligning automation and digital manufacturing with project delivery, CQV, quality, and operational readiness. That fits a consulting firm that wants to reach pharma manufacturing, engineering, quality, and CQV leaders with timely sector updates and acquisition-integration commentary.
- Bob Cormier: Choose Bob Cormier over Jason Hier when the campaign is about regional life sciences economic development, public funding, incentives, or site selection rather than pharma strategy-to-execution consulting. Cormier's posts walk through Rhode Island's life sciences ecosystem with specific dollar figures across NIH awards, university gifts, manufacturing investment, incubators, and state facilities, and argue that retention of existing companies should sit alongside attraction. That is a strong fit for an economic development organization, a site-selection campaign, or a public-affairs collaboration with a place-based audience.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/